ImmuPharma (LON:IMM) Trading 4.9% Higher – Still a Buy?

ImmuPharma plc (LON:IMMGet Free Report)’s stock price shot up 4.9% during mid-day trading on Friday . The company traded as high as GBX 4.70 ($0.06) and last traded at GBX 3.67 ($0.05). 109,382,164 shares changed hands during mid-day trading, an increase of 245% from the average session volume of 31,664,631 shares. The stock had previously closed at GBX 3.50 ($0.04).

ImmuPharma Stock Performance

The business has a 50 day moving average of GBX 1.40 and a two-hundred day moving average of GBX 1.65. The firm has a market capitalization of £15.30 million, a price-to-earnings ratio of -367.30 and a beta of 1.53.

About ImmuPharma

(Get Free Report)

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.

Featured Stories

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.